Samantha Williams, MD
Infectious Disease · West Columbia, SCNPI 1114422821
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $579 and has fallen 55.8% since, to $256 in 2025. That places this record below the midpoint for infectious disease clinicians in SC, where the typical reported total is $781.
Across 39 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$123
- Astellas Pharma US Inc$93
- Gilead$91
- Shionogi Inc$86
- Viiv Healthcare Company$81
- Paratek Pharmaceuticals, Inc.$59
- plus $385 from 13 others
What the payments were for
- Food & beverage$88496%
- Education$354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$919 in reported general payments places this provider in the 50th percentile of 102 infectious disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 45 | $34,472 |
| Tigecycline | 11 | $2,696 |
| Ampicillin Sodium | 11 | $2,499 |
| CeftriaxoneCeftriaxone Sodium | 29 | $2,057 |
| Cefazolin Sodium | 36 | $1,784 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 15 | $1,678 |
| Meropenem | 12 | $1,091 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $490 |
| CefoxitinCefoxitin Sodium | 11 | $372 |
| Amikacin Sulfate | 11 | $252 |
| Doxycycline Hyclate | 17 | $197 |
| Ciprofloxacin Hcl | 11 | $165 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in West Columbia
- Emilio Perez JorgeWest Columbia$3K
- Elizabeth NimmichWest Columbia$2K
- Natalie CauthenWest Columbia$706
- Rebecca BerdelWest Columbia$668
- Timothy HenkelHilton Head Island$1.8M
- Toby FugateCharleston$136K
- John McKinnonCharleston$85K
- John SchrankGreenville$74K
- Rishika MotianiFlorence$43K
- John GnannCharleston$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.